Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

41 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Consensus report: clinical recommendations for the prevention and management of the nocebo effect in biosimilar-treated IBD patients.
Pouillon L, Danese S, Hart A, Fiorino G, Argollo M, Selmi C, Carlo-Stella C, Loeuille D, Costanzo A, Lopez A, Vegni E, Radice S, Gilardi D, Socha M, Fazio M, González-Lorenzo M, Bonovas S, Magro F, Peyrin-Biroulet L. Pouillon L, et al. Among authors: argollo m. Aliment Pharmacol Ther. 2019 May;49(9):1181-1187. doi: 10.1111/apt.15223. Epub 2019 Apr 1. Aliment Pharmacol Ther. 2019. PMID: 30932219
Biosimilars of adalimumab: the upcoming challenge in IBD.
Fiorino G, Gilardi D, Correale C, Furfaro F, Roda G, Loy L, Argollo M, Allocca M, Peyrin-Biroulet L, Danese S. Fiorino G, et al. Among authors: argollo m. Expert Opin Biol Ther. 2019 Oct;19(10):1023-1030. doi: 10.1080/14712598.2019.1564033. Epub 2019 Jan 8. Expert Opin Biol Ther. 2019. PMID: 30601098 Review.
Multidisciplinary management of the nocebo effect in biosimilar-treated IBD patients: Results of a workshop from the NOCE-BIO consensus group.
D'Amico F, Pouillon L, Argollo M, Hart A, Fiorino G, Vegni E, Radice S, Gilardi D, Fazio M, Leone S, Bonovas S, Magro F, Danese S, Peyrin-Biroulet L. D'Amico F, et al. Among authors: argollo m. Dig Liver Dis. 2020 Feb;52(2):138-142. doi: 10.1016/j.dld.2019.11.004. Epub 2019 Dec 4. Dig Liver Dis. 2020. PMID: 31812570 Review.
Novel therapeutic targets for inflammatory bowel disease.
Argollo M, Fiorino G, Hindryckx P, Peyrin-Biroulet L, Danese S. Argollo M, et al. J Autoimmun. 2017 Dec;85:103-116. doi: 10.1016/j.jaut.2017.07.004. Epub 2017 Jul 12. J Autoimmun. 2017. PMID: 28711286 Review.
Vedolizumab for the treatment of Crohn's disease.
Argollo M, Fiorino G, Peyrin-Biroulet L, Danese S. Argollo M, et al. Expert Rev Clin Immunol. 2018 Mar;14(3):179-189. doi: 10.1080/1744666X.2018.1438189. Epub 2018 Feb 23. Expert Rev Clin Immunol. 2018. PMID: 29406811 Review.
PF-00547659 for the treatment of Crohn's disease and ulcerative colitis.
Allocca M, Gilardi D, Fiorino G, Furfaro F, Argollo M, Peyrin-Biroulet L, Danese S. Allocca M, et al. Among authors: argollo m. Expert Opin Investig Drugs. 2018 Jul;27(7):623-629. doi: 10.1080/13543784.2018.1494722. Epub 2018 Jul 16. Expert Opin Investig Drugs. 2018. PMID: 29985060 Review.
Loss of Response to Vedolizumab and Ability of Dose Intensification to Restore Response in Patients With Crohn's Disease or Ulcerative Colitis: A Systematic Review and Meta-analysis.
Peyrin-Biroulet L, Danese S, Argollo M, Pouillon L, Peppas S, Gonzalez-Lorenzo M, Lytras T, Bonovas S. Peyrin-Biroulet L, et al. Among authors: argollo m. Clin Gastroenterol Hepatol. 2019 Apr;17(5):838-846.e2. doi: 10.1016/j.cgh.2018.06.026. Epub 2018 Jun 20. Clin Gastroenterol Hepatol. 2019. PMID: 29935327
Comorbidities in inflammatory bowel disease: a call for action.
Argollo M, Gilardi D, Peyrin-Biroulet C, Chabot JF, Peyrin-Biroulet L, Danese S. Argollo M, et al. Lancet Gastroenterol Hepatol. 2019 Aug;4(8):643-654. doi: 10.1016/S2468-1253(19)30173-6. Epub 2019 Jun 3. Lancet Gastroenterol Hepatol. 2019. PMID: 31171484 Review.
41 results